Close
FINDING CURES TOGETHER<sup>SM</sup>

CICR Election Results

Congratulations to Philip Jones, PhD, CICR Chairperson-elect 2019-2020

Our thanks to James E. Audia, PhD, and Philip Jones, PhD, for standing for election, and to the CICR membership for participating in the election. We congratulate Dr. Jones on his election as CICR chairperson-elect. Dr. Jones will assume the office of chairperson-elect at the AACR Annual Meeting 2019, March 29-April 3, in Atlanta, Georgia.

Philip Jones, PhD
Vice President, Therapeutics Discovery, and Head of Drug Discovery
Institute for Applied Cancer Science
UT MD Anderson Cancer Center
Houston, Texas

Education:
1996
PhD, Organic Chemistry
University of Nottingham, UK

Other Positions Currently Held:
Founder, Magnolia Neurosciences, 2018
Founder, Navire Pharma, 2017
Founder, Vescor Therapeutics, 2017

Research Interests/Vision Statement

I am a seasoned drug hunter, having worked for more than 20-years in industry and academia, both at Merck and at MD Anderson Cancer Center. I am the inventor of the approved PARP inhibitor niraparib, and have led teams to advances multiple other molecules into the clinic. I currently lead the drug discovery efforts at the Institute for Applied Cancer Science.

Besides classical small molecule modulators of protein targets, I have developed an ADC platform; worked on programs outside of classical rule-of-five space; developed protein degradation approaches; and used chemical probes for target (in)validation. I adopt an opportunistic approach to seeding programs, and have been successful utilizing fragment based, natural products, and DNA encoded libraries, as well as classical HTS to enable drug discovery projects. I am a widely respected cancer drug developer, and well-recognized as a translational scientist well-versed in cancer biology and clinical development.

As a drug developer, I recognize the pivotal role of chemistry as an enabler and fundamental part of cancer research, and see the chance for the Chemistry in Cancer Research Working Group (CICR) in shaping cancer research into the 2020’s. This is an exciting time for CICR with the explosion in new therapeutic targets including protein-DNA/RNA targets; non-conventional modalities outside of Ro5 space; leveraging protein degradation technology; new delivery vehicles; and small molecule-protein conjugates. I recognize the role chemistry plays in diagnostics, imaging and in tools to enable research.

My vision for CICR is as a vehicle to make the cancer community recognize the pivotal role of chemistry in changing patients’ lives.